Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel disease
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf376 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Brigida Barberio und 17 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova, Padova 35100, Italy. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Machine Learning, Colitis, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have revolutionized oncology by enhancing antitumor immune responses. However, their use is frequently associated with immune-mediated adverse events, including colitis (ICIs-colitis). This condition shares clinical and histological features with inflammatory bowel diseases (IBD), such as Crohn’s disease (CD) and ulcerative colitis (UC). Emerging evidence highlights the gut microbiota’s role in both ICIs-colitis and IBD pathogenesis. This study aimed to determine whether a distinct microbiota profile, assessed via machine learning, could differentiate ICIs-colitis from IBD and healthy controls (HCs).
Methods
A prospective study was conducted with patients diagnosed with ICIs-colitis, alongside historical cohorts of IBD patients (active and inactive UC/CD) and HCs. Stool samples were analyzed using 16S rRNA gene sequencing. Diversity metrics (alpha and beta) and differential abundance at multiple taxonomic levels were evaluated. Machine learning techniques, including supervised and unsupervised algorithms, were employed to identify microbiota patterns and signatures distinguishing the groups.
Results
Nineteen patients with ICIs-colitis, 40 with UC (20 active, 20 inactive), 34 with CD (14 active, 20 inactive), and 36 HCs were analyzed. Alpha diversity differed between ICI-colitis and UC (P = .03) and between ICI-colitis and CD (P = .0002), but not versus healthy controls (P = .94). Beta diversity showed significant disease-associated clustering among ICI-colitis, UC and CD (PERMANOVA P < .001). Differential abundance analyses identified higher Enhydrobacter in ICI-colitis versus IBD and higher Bifidobacterium longum in UC. Machine-learning approaches (sparse partial least squares discriminant analysis, sPLS-DA, and Random Forest) supported group discrimination.
Conclusion
A unique microbiota signature characterizes ICIs-colitis compared to IBD and HCs. These findings underscore the potential of microbiota profiling and machine learning to aid in diagnosing and managing ICIs-colitis. Future studies should validate these findings in larger, multicenter cohorts, and explore therapeutic implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova, Padova 35100, Italy.
- Research & Development Division, EuBiome Srl, Via della Croce Rossa 112, Padova, Veneto 35100, Italy.
- Gastroenterology Unit, Department of Gastrointestinal Oncological Surgery, S. Maria del Prato Hospital, Feltre 32032, Italy.
- Veneto Institute of Oncology IOV-IRCCS, Padova 35100, Italy.
- BMR Genomics Via Redipuglia 22, Padova 35100, Italy.
- Surgical Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padova 35100, Italy.
ORCID-Profile: Brigida Barberio, Luisa Bertin, Alessandro Dal Maso, Stefano Frega, Fabiana Zingone, Angelo Paolo Dei Tos
Förderung
- Italian Ministry of Health
Zitieren
APA
Barberio, B., Patuzzi, I., Bertin, L., Facchin, S., De Ruvo, M., Bonazzi, E., De Barba, C., Dal Maso, A., Frega, S., Simionati, B., Sattin, E., Buda, A., Zingone, F., Burra, P., Dei Tos, A. P., Pasello, G., Bonanno, L., & Savarino, E. V. (2025). Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel disease. The Oncologist. https://doi.org/10.1093/oncolo/oyaf376
Vancouver
Barberio B, Patuzzi I, Bertin L, Facchin S, De Ruvo M, Bonazzi E, et al. Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel disease. The Oncologist. 2025. doi:10.1093/oncolo/oyaf376
BibTeX
@article{Barberio2025,
author = {Barberio, Brigida and Patuzzi, Ilaria and Bertin, Luisa and Facchin, Sonia and De Ruvo, Marianna and Bonazzi, Erica and De Barba, Caterina and Dal Maso, Alessandro and Frega, Stefano and Simionati, Barbara and Sattin, Eleonora and Buda, Andrea and Zingone, Fabiana and Burra, Patrizia and Dei Tos, Angelo Paolo and Pasello, Giulia and Bonanno, Laura and Savarino, Edoardo Vincenzo},
title = {Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel disease},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf376}
}
EUVIMED